EUCTR2019-001639-30-ES进行中（未招募）1 期
Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients: CABOMAYOR study
Spanish Oncology Genitourinary Group - SOGUG0 个研究点目标入组 50 人开始时间: 2019年8月9日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Documented histological or cytological diagnosis of renal cell cancer.
- •2. Measurable disease per RECIST 1.1 as determined by the investigator.
- •3. Metastatic disease.
- •4. Patient must have signed the informed consent document.
- •5. Capable of understanding and complying with the protocol requirements.
- •6. ECOG-PS 0-2.
- •7. Patients aged >70 years old with SIOG (Society of Geriatric Oncology) defined fragile population or patients >75 years with or without SIOG defined fragility.
- •8. No previous treatment for mRCC.
- •9. Adequate organ function based on standard laboratory tests including haematology, serum chemistry, lipids, coagulation, thyroid function, and urinalysis.
- •a. Absolute neutrophil count (ANC) = 1500/mm3.
- •b. Platelets = 100,000/mm3.
- •c. Hemoglobin = 9 g/dL (= 90 g/L).
- •d. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3.0 × upper limit of normal.
- •e. Total bilirubin = 1.5 × the upper limit of normal. For subjects with Gilbert’s disease = 3 mg/dL (= 51.3 µmol/L).
- •f. Fasting serum triglycerides = 2.5 × upper limit of normal AND total cholesterol = 300 mg/dL (= 7.75 mmol/L). Lipid-lowering medication is allowed.
- •g. HbA1c = 8%. For subjects with a condition (eg, hemoglobin variant) that affects the interpretation of HbA1c results, a fasting glucose = 160 mg/dL (= 8.9 mmol/L).
- •h. Serum creatinine = 2.0 × upper limit of normal or calculated creatinine clearance = 30 mL/min (= 0.5 mL/sec) using the Cockroft-Gault equation (see section 10.7.5).
- •i. Urine protein-to-creatinine ratio (UPCR) = 1 mg/mg (= 113.2 mg/mmol) creatinine or 24-hour urine protein < 1 g.
- •10. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Previous treatment for mRCC.
- •2. Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before inclusion.
- •3. Known brain metastases or cranial epidural disease unless adequately treated and stable for at least 3 months before inclusion. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of inclusion.
- •4. Concomitant anticoagulation at therapeutic doses with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel). Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (< 1 mg/day), and low dose, low molecular weight heparins (LMWH) are permitted.
- •5. Chronic treatment with corticosteroids or other immunosuppressive agents (with the exception of inhaled or topical corticosteroids or corticosteroids with a daily dosage equivalent = 10 mg prednisone if given for disorders other than renal cell cancer). Subjects with brain metastases requiring systemic corticosteroid are not eligible.
- •6. Uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
- •a. Cardiovascular disorders:
- •i. Congestive heart failure New York Heart Association class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.
- •ii. Uncontrolled hypertension defined as sustained BP > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment.
- •iii. Stroke (including TIA), myocardial infarction, or other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before inclusion.
- •b. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:
- •i. Tumors invading the GI-tract, active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction.
- •ii. Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before inclusion. Note: Complete healing of an intra-abdominal abscess must be confirmed before inclusion.
- •c. Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 3 months before inclusion.
- •d. Cavitating pulmonary lesion(s) or known endobronchial disease manifestation.
- •e. Lesions invading major pulmonary blood vessels.
- •f. Other clinically significant disorders such as:
- •i. Active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)- related illness, or chronic hepatitis B or C infection.
- •ii. Serious non-healing wound/ulcer/bone fracture.
- •iii. Malabsorption syndrome.
- •iv. Uncompensated/symptomatic hypothyroidism.
- •v. Moderate to severe hepatic impairment (Child-Pugh B or C).
- •vi. Requirement for hemodialysis or peritoneal dialysi
研究者
相似试验
招募中
1 期
Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasOsteosarcomaEwing SarcomaNCT06156410Children's Hospital of Philadelphia30
已完成
1 期
Study of Cabozantinib Plus TAS102 in mCRC as Salvage TherapyColorectal CarcinomaMetastatic CancerColorectal CancerCRCNCT04868773University of California, Irvine15
已完成
1 期
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid TumorsSolid TumorNCT03611595Peter Zage15
进行中（未招募）
1 期
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsUrothelial CarcinomaCastration-resistant Prostate CancerTriple Negative Breast CancerEndometrial CancerGastroesophageal Junction AdenocarcinomaColorectal CancerOvarian CancerGastric CancerHead and Neck CancerDifferentiated Thyroid CancerLower Esophageal CancerRenal Cell CarcinomaHepatocellular CarcinomaNon-Small Cell Lung CancerNCT03170960Exelixis914
已完成
1 期
METBEIGE Studycolorectal cancerJPRN-jRCT2080224606ational Cancer Center Hospital East54